DZ964A1 - Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée. - Google Patents

Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée.

Info

Publication number
DZ964A1
DZ964A1 DZ860158A DZ860158A DZ964A1 DZ 964 A1 DZ964 A1 DZ 964A1 DZ 860158 A DZ860158 A DZ 860158A DZ 860158 A DZ860158 A DZ 860158A DZ 964 A1 DZ964 A1 DZ 964A1
Authority
DZ
Algeria
Prior art keywords
sustained
release pharmaceutical
pharmaceutical forms
drug
obtaining solid
Prior art date
Application number
DZ860158A
Other languages
English (en)
French (fr)
Inventor
Rosa Martani
Le Elisabeth Huede
Jeanne Dumas
Original Assignee
Cortial
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortial filed Critical Cortial
Application granted granted Critical
Publication of DZ964A1 publication Critical patent/DZ964A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DZ860158A 1985-07-26 1986-07-23 Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée. DZ964A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8511575A FR2585246A1 (fr) 1985-07-26 1985-07-26 Procede d'obtention de formes pharmaceutiques solides a liberation prolongee

Publications (1)

Publication Number Publication Date
DZ964A1 true DZ964A1 (fr) 2004-09-13

Family

ID=9321740

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ860158A DZ964A1 (fr) 1985-07-26 1986-07-23 Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée.

Country Status (13)

Country Link
US (1) US4834965A (pt)
EP (1) EP0214735B1 (pt)
AT (1) ATE66599T1 (pt)
AU (1) AU585377B2 (pt)
CA (1) CA1304684C (pt)
DE (1) DE3681099D1 (pt)
DZ (1) DZ964A1 (pt)
ES (1) ES2000555A6 (pt)
FR (1) FR2585246A1 (pt)
MA (1) MA20745A1 (pt)
OA (1) OA08368A (pt)
PT (1) PT83052B (pt)
ZA (1) ZA865455B (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750145T2 (de) * 1986-06-10 1994-11-03 Euro Celtique Sa Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein.
DE3856555T2 (de) * 1987-10-16 2004-04-29 Elan Corp. Plc Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
AU3432689A (en) * 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
FR2630913A1 (fr) * 1988-05-09 1989-11-10 Delalande Sa Comprimes de sel(s) hydrosoluble(s) de diltiazem a liberation programmee et leur procede de fabrication
NL8902338A (nl) * 1988-09-20 1990-04-17 Glaxo Group Ltd Farmaceutische preparaten.
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
DE69311394T2 (de) * 1992-02-20 1997-10-30 Euro Celtique Sa Arzneimittel verzögerter Wirkstoffabgabe
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
DE69432867T2 (de) * 1993-11-18 2004-04-22 Sirtex Medical Ltd., Burswood Zubereitung mit gesteuerter freisetzung
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US6063370A (en) * 1996-04-05 2000-05-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク,エス.エイ. オピオイド作動薬/拮抗薬の併用
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6417237B1 (en) * 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
CA2547847A1 (en) * 2003-12-18 2005-07-07 Huntsman Petrochemical Corporation Surfactant enhanced quick release pesticide granules
MXPA06012564A (es) * 2004-04-27 2007-01-31 Medicinova Inc Derivados de acido fenoxialquilcarboxilico en el tratamiento de enfermedades inflamatorias.
JP4805256B2 (ja) * 2004-05-14 2011-11-02 グリーン・クロス・コーポレイション 右旋性モルヒナンの神経保護特性
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
ES2531735T3 (es) * 2004-10-15 2015-03-18 Supernus Pharmaceuticals, Inc. Preparaciones farmacéuticas con menor potencial de abuso
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
BRPI0611272A2 (pt) * 2005-05-03 2011-11-16 Mutual Pharmaceutical Co formulações de quinina
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
RU2478388C2 (ru) * 2008-07-07 2013-04-10 Еуро-Селтик С.А. Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
EP2381937A2 (en) * 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
BR112016001400B1 (pt) 2013-07-25 2023-02-28 Medicinova, Inc Uso de ácidos fenoxialquilcarboxílicos para preparação de medicamentos para a redução de níveis sanguíneos de triglicerídeos, colesterol total e lipoproteínas de baixa densidade
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
JP6469727B2 (ja) 2014-06-02 2019-02-13 メディシノバ・インコーポレイテッドMediciNova, Inc. 線維症の抑制又は治療方法
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
KR102462638B1 (ko) 2014-11-26 2022-11-03 메디시노바, 인크. 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
CA3217719A1 (en) 2021-05-28 2022-12-01 Kazuko Matsuda Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2802114A1 (de) * 1978-01-19 1979-07-26 Sandoz Ag Neue pharmazeutische zusammensetzung und verfahren zu deren herstellung
FR2523446A1 (fr) * 1982-03-19 1983-09-23 Dietlin Francois Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release

Also Published As

Publication number Publication date
US4834965A (en) 1989-05-30
AU6058386A (en) 1987-01-29
PT83052A (en) 1986-08-01
OA08368A (fr) 1988-02-29
ES2000555A6 (es) 1988-03-01
MA20745A1 (fr) 1987-04-01
FR2585246A1 (fr) 1987-01-30
EP0214735B1 (en) 1991-08-28
ATE66599T1 (de) 1991-09-15
EP0214735A1 (en) 1987-03-18
CA1304684C (en) 1992-07-07
PT83052B (pt) 1988-07-01
AU585377B2 (en) 1989-06-15
ZA865455B (en) 1987-03-25
DE3681099D1 (de) 1991-10-02

Similar Documents

Publication Publication Date Title
DZ964A1 (fr) Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée.
DZ1923A1 (fr) Sels d'un derivé d'indole anti-migraineux, son Procédé de production et composition pharmaceutique le contenant.
FR2599027B1 (fr) Derives de tetrahydronaphtalene et d'indane, utilisation pour la fabrication de preparations pharmaceutiques et procede d'obtention.
OA08871A (fr) Nouveaux dérivés de thiazole actif sur le système cholinergique, procédé d'obtention et compositions pharmaceutiques en contenant.
FR2629344B1 (fr) Preparation pharmaceutique a liberation controlee et procede pour sa production
DZ2786A1 (fr) Préparation pharmaceutique de sildénafil à délitement oral et procédé por sa production.
OA08192A (fr) Nouveau procédé d'obtention de formes pharmaceutiques à libération prolongée.
PT81091B (pt) Processo para a preparacao de comprimidos de libertacao constante
FI850449A7 (fi) Menetelmä (-)-trans-4-(4-fluorifenyyli) -3-(4-metoksifenoksi)-metyylipiperidiinin tai sen farmaseuttisesti hyväksyttävien happoadditiosuolojen valmistamiseksi.
AT323719B (de) Verfahren zur herstellung von neuen n-hydroxyphenylalkyl-beta-(3,4-dihydroxyphenyl)-äthylaminen und deren pharmazeutisch annehmeaben mineralsäureadditionssalzen
EP0357565A3 (en) New process for the synthesis of the levodopa
EP0776873A3 (en) Aqueous emulsion of alkylalkoxysilanes, process for their preparation and their use
BR8803697A (pt) Processo para a preparacao de um polimero hidrogenado funcionalizado e copolimero funcionalizado
PT92789A (pt) Processo para a preparacao de um polimero a base de cloreto de vinilo
IT8922135A0 (it) Processo per la produzione di soluzioni acquose di agenti anti-incrostazione e soluzioni cosi' ottenute
FR2505330B1 (fr) Nouvelle substance carcinostatique a base d'un derive de n-(4-(3-aminopropyl) aminobutyl)-2-((s)-7-guanidino-3-hydroxyhaptanamido)-2-hydroxyethanamide et son procede de preparation
OA06469A (fr) Procédé d'obtention d'acides aminés à partir d'hydrolysats de protéines.
FR2627986B1 (fr) Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazol-4-one ou d'un de ses sels et de dexamethasone, son procede de preparation et ses utilisations
DE58908990D1 (de) Synthetische Vakzine gegen die Maul- und Klauenseuche und Verfahren zu deren Herstellung.
IT1165058B (it) Processo per la preparazione di polimeri graffati di alfa,alfa' disostituiti beta-propiolattoni su copolieri a base di isobutilene e trieni
DZ2757A1 (fr) Procédé pour la préparation d'acides hydroxamiques.
BR9101617A (pt) Processo para a producao de agentes de ativacao a base de fosfato de titanio(iv),aplicacao desses agentes,mistura de ativacao e limpeza,e os ditos agentes
MA19021A1 (fr) Procede de preparation de compositions pharmaceutiques a base d'alpha-12-bis(i methyl ethyl)amino/alpha-phenyl 2-pyridine acetamide ou de l'un de ses sels
FR2709961B1 (fr) Forme pharmaceutique moulée pour administration orale à base d'acide acétylsalicylique ou de ses sels et son procédé de fabrication.
FR2583419B1 (fr) Procede pour la preparation de 2-bromo-a-ergocryptine et ses sels d'addition d'acides.